Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?
SGLT-2抑制剂在射血分数降低或保持不变的心力衰竭患者中是否显示出类似的心血管益处?
Corresponding Author
Awadhesh Kumar Singh
Department of Diabetes & Endocrinology, G.D Hospital & Diabetes Institute, Kolkata, India
Correspondence
Awadhesh Kumar Singh, G.D Hospital & Diabetes Institute, Kolkata, 700014, India.
Email: [email protected]
Search for more papers by this authorRitu Singh
Department of Diabetes & Endocrinology, G.D Hospital & Diabetes Institute, Kolkata, India
Search for more papers by this authorAnoop Misra
Department of Diabetes, Fortis-CDOC hospital for Diabetes & Allied Science, New Delhi, India
Search for more papers by this authorCorresponding Author
Awadhesh Kumar Singh
Department of Diabetes & Endocrinology, G.D Hospital & Diabetes Institute, Kolkata, India
Correspondence
Awadhesh Kumar Singh, G.D Hospital & Diabetes Institute, Kolkata, 700014, India.
Email: [email protected]
Search for more papers by this authorRitu Singh
Department of Diabetes & Endocrinology, G.D Hospital & Diabetes Institute, Kolkata, India
Search for more papers by this authorAnoop Misra
Department of Diabetes, Fortis-CDOC hospital for Diabetes & Allied Science, New Delhi, India
Search for more papers by this author摘要
SGLT-2抑制剂(SGLT-2i)对心力衰竭患者的心血管有益已为人所知。SGLT-2i在射血分数降低或保持不变的心力衰竭患者中是否具有类似的心血管效应尚不清楚。这项meta分析显示，SGLT-2i与心力衰竭的类型无关，具有相似的心血管益处。未来的试验将证实或驳斥SGLT-2i对射血分数保持不变的心力衰竭患者的心血管效应。
Supporting Information
| Filename | Description |
|---|---|
| jdb13182-sup-0001-FigureS1.JPGJPEG image, 146.4 KB | Figure S1 PRISMA flow-diagram |
| jdb13182-sup-0002-FigureS2.JPGJPEG image, 61.6 KB | Figure S2 Funnel plot for publication bias |
| jdb13182-sup-0003-Tables.docxWord 2007 document , 16.7 KB | Table S1 Risk of bias in randomized controlled trials (RCTs) of sodium glucose cotransporter-2 (SGLT-2) inhibitors in patients with heart failure with or without diabetes. Table S2: Final results and sensitivity (influence) analysis after the exclusion of each trial |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Fitchett D, Butler J, van de Borne P, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J. 2018; 39(5): 363-370.
- 2Radholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation. 2018; 138(5): 458-468.
- 3Kato ET, Silverman MG, Mosenzon O, et al. Effect of Dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019; 139(22): 2528-2536.
- 4Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of Ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation. 2020; 142: 2205-2215. https://doi.org/10.1161/CIRCULATIONAHA.120.050255.
- 5Sarraju A, Li J, Cannon CP, et al. Canagliflozin reduces cardiovascular and renal events independent of baseline heart failure: a credence secondary analysis. J Am Coll Cardiol. 2020; 75(11): 1018.
- 6Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021; 384: 129-139. https://doi.org/10.1056/NEJMoa2030186.
- 7McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381: 1995-2008.
- 8Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with Empagliflozin in heart failure. N Engl J Med. 2020; 383: 1413-1424. https://doi.org/10.1056/NEJMoa2022190.
- 9Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021; 384: 117-128. https://doi.org/10.1056/NEJMoa2030183.
- 10Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928.
- 11Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-560.
- 12Singh AK, Singh R. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies. Expert Rev Clin Pharmacol. 2019; 12(4): 299-308.
- 13Nassif ME, Kosiborod M. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure. Diabetes Obes Metab. 2019; 21(Suppl 2): 19-23.
- 14Singh AK, Singh R. Cardiovascular outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Syndr. 2021; 15(1): 351-359.
- 15Anker SD, Butler J, Filippatos G, et al. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-preserved trial. Eur J Heart Fail. 2020; 22: 2383-2392. https://doi.org/10.1002/ejhf.2064.
- 16 Dapagliflozin Evaluation to Improve the LIVEs of Patients with Preserved Ejection Fraction Heart Failure (DELIVER). NCT03619213. https://clinicaltrials.gov/ct2/show/NCT03619213. Accessed on December 15, 2020
Citing Literature
